Understand the source comparison
SS-31 Cycle Length: Research Protocol Comparison
Understanding how SS-31 cycle length varies across research objectives requires examining the evidence across multiple study types. The following comparison synthesizes protocols from preclinical models, human clinical trials, and mechanistic studies to clarif
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding how SS-31 cycle length varies across research objectives requires examining the evidence across multiple study types. The following comparison synthesizes protocols from preclinical models, human clinical trials, and mechanistic studies to clarify which cycle length aligns with which research endpoint.
- Acute cardioprotection (ischemia-reperfusion)
- Single dose to 48 hours
- Single bolus or 1-hour infusion before/during reperfusion
- Infarct size, troponin release, LV function at 24–72 hours
- Effective for immediate mitochondrial stabilization; does not address chronic remodeling
- Chronic heart failure or cardiomyopathy
- 4–12 weeks
- Once daily subcutaneous injection
- LVEF, diastolic function, exercise capacity, quality of life scores
- 8–12 weeks required for structural cardiac remodeling; 4 weeks shows functional improvement only
- Skeletal muscle mitochondrial function
- 6–12 weeks
- Maximal oxygen consumption (VO2max), citrate synthase activity, cristae density
- Minimum 6 weeks needed; 8–12 weeks captures mitochondrial biogenesis and remodeling
- Metabolic research (insulin sensitivity, obesity)
- 8–12 weeks
- Glucose tolerance (AUC), insulin sensitivity index, body composition, energy expenditure
- 8 weeks minimum to detect changes in substrate oxidation and whole-body energy balance
- Neurodegenerative disease models
- 8–16 weeks
- Cognitive testing, neuronal ATP content, synaptic density, neuroinflammation markers
- Longest cycle length required due to slow neuronal mitochondrial turnover
- Aging and mitochondrial myopathy
- 12 weeks (clinical standard)
- Six-minute walk distance, fatigue scales, skeletal muscle biopsy ATP production
- 12-week duration established in phase 2 trial; functional gains plateau after week 8–12
- This comparison clarifies a critical distinction: acute SS-31 administration rescues mitochondrial function under stress, while chronic administration drives mitochondrial biogenesis and structural adaptation. Research teams studying acute events. Such as myocardial infarction, stroke, or traumatic injury. Can use cycle lengths measured in hours to days. Teams studying chronic conditions. Heart failure, sarcopenia, metabolic syndrome, neurodegenerative disease. Must plan for 8–12 week protocols to capture the full scope of mitochondrial remodeling. Attempting to measure structural endpoints at 2–4 weeks will produce false-negative results because the biological process hasn't had sufficient time to manifest.